CAS BIOFINDER DISCOVERY PLATFORM™

快速使用指南 (QUICK GUIDE)

CAS
A division of the
American Chemical Society

大綱

- CAS BioFinder簡介與界面介紹
- 配體檢索與配体詳情信息（配體與細節概述）
- 骨架檢索與構效關係分析（支架與搜救分析）
- 蛋白/通路/靶點、疾病與生物標誌物（Proteins and Pathways;疾病與生物標記）
- 生物活性預測（Predictive Analytics）

科學資訊管理對新藥研發至關重要

低增長時代的特點對創新的要求極大提升，而在當今的創新環境下，數據管理任務艱巨

- 信息鴻溝會導致創新管線薄弱、研發效率低下，以及意外的知識產權風險
- 由於數據量和數據類型日益複雜，藥物發現流程中，整合和分析關鍵的研發數據資訊，對於迅速做出關鍵決策至關重要。
- 持續的數據管理有助於開發差異化的成果，支撐創新藥物的發現，確保藥物研發成功進入審批階段，並可避免後續智慧財產權問題。

来源：CAS Insights洞察报告 Challenges and opportunities in data for drug discovery | CAS

CAS
A division of the American Chemical Society

生命科學領域研究離不開重要的數據資訊基礎，但為什麼卻難以加以利用？

缺乏關聯性

生命科學研究和數據分散在各個資料庫、

期刊和專利等眾多互不關聯的資源之中



未一致化

不同資源對相同資訊的描述各不相同，因此很難對數據進行分析和比較

CAS
A division of the American Chemical Society

數據問題導致延緩創新進程，增加財務風險

遺漏見解

這些見解能夠為研究人員制定研發戰略提供指導

僅在美國，每年就有5,000到6,000起專利侵權和專利無效的訴訟，法院判定的賠償金額接近 50 億美元[1]。

耗費時間



生命科學數據量每 14 年翻一番[2]

數據科學家將 50%-80% 的時間都花費在收集和整理用於分析模型的數據資訊的瑣碎的工作中[3]

1. Vuleta, B. (2023). 25 Patent Litigation Statistics - High-Profile Feuds about Intellectual Property. LegalJobs. https://legaljobs.io/blog/patent-litigation-statistics/
2. Bornmann, L. et al. (2021). Growth rates of modern science: a latent piecewise growth curve approach to model publication numbers from established and new literature databases. (Humanities and Social Sciences Communications), 8, 224. https://doi.org/10.1057/s41599-021-00903-w
3. Lohr, S. (2014.) For Big-Data Scientists, 'Janitor Work' Is Key Hurdle to Insights. The New York Times. August 17, 2014. https://www.nytimes.com/2014/08/18/technology/for-big-data-scientists-hurdle-to-insights-is-janitor-work.html
4. Genetic Engineering & Biotechnology News Top 25 Biotech Companies of 2019. 5. Pharm Exec's Top 50 Companies 2020.6. Shanghai Ranking's Global Ranking of Academic Subjects 2020.

CAS
A division of the American Chemical Society

利用CAS BioFinder 加速早期藥物研發

預測新型分子可能對生物過程產生的影響

識別與您感興趣的疾病或靶點相關的骨架和分子

發現與您感興趣的疾病相關的生物標誌物

找出哪些候選藥物最有可能成為最安全、最佳的先導化合物

持續開發中的更多內容與功能（序列、抗體、PDC、藥物情報等）

CAS
A division of the American Chemical Society

CAS BioFinder檢索介面

CAS
A division of the American Chemical Society

大綱

- CAS BioFinder簡介與檢界面介紹（介紹與介面）
- 配體檢索與配體詳情信息（配體與細節概述）
- 骨架檢索與構效關係分析（支架與搜救分析）
- 蛋白/通路/靶點、疾病與生物標誌物（Proteins and Pathways; 疾病與生物標記）
- 生物活性預測（Predictive Analytics）

基於靶點、疾病、藥物名稱以及結構，檢索資訊



CAS
A division of the American Chemical Society

篩選具有類似先導化合物特性的小分子配體

一鍵應用Rule of 5



- 氫键受體<10
- 氫键供體<5
- 自由旋轉键 <10
- 分子量 <500
- 摩尔折射率：
  40-130 m³/mol
- 原子数: 20-70

- logP <5
- 极性表面积：
  0-140 Å²

CAS
A division of the American Chemical Society

配體檢索結果的縱覽與聚焦



CAS
A division of the American Chemical Society

縱覽配體檢索結果集相關骨架結構與藥理學數據

查看配體檢索結果關聯的骨架結構

數據可視化:

- 柱狀/折線圖：每條柱形/折線節點
- 代表針對不同靶點的測量實驗數量調節圖下方的橫條，可放大圖表的特定區域

可下載表格中的詳細數據

點擊View，可查看原文中的Assay的細節

CAS
A division of the American Chemical Society

探索配體的詳細資訊



CAS
A division of the American Chemical Society

藥物情報資訊(Drug Intelligence)

CAS DRUG INTELLIGENCE — Approved Drug

Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of...

View More

STATUS

Approval Status: US Approved
Approval Authority: US FDA
Approval Year: 1974, 2024
Originator: Farmitalia

INDICATIONS

Ovarian cancer
Modality: Primary
Highest Phase: Approved
Source

View All

PRIMARY TARGET

DNA topoisomerase II
Function: Inhibitor
Measurement: IC50 2.67 µM
Source

View All

View Related Drugs

Targets 相關靶標

Primary Target	Function	Measurement
DNA topoisomerase II	Inhibitor	IC50 2.67 µM
Albumin	Binding Agent	-
DNA gyrase	Inhibitor	-
DNA topoisomerase II	Inhibitor	IC50 2.67 µM
A673	Inhibitor	IC50 200.0 nM
HepG2	Inhibitor	IC50 24.68 µM
Human ovarian cancer cell line	Inhibitor	IC50 0.074 µM

Indications 相關適應症　所處臨床階段和獲批資訊

Name	Modality	Highest Phase	Source
Ovarian cancer	Primary	Approved	View
AIDS-related Kaposi's sarcoma	Primary	Approved	View
Multiple myeloma	Primary	Approved	View
Locally advanced or unresectable soft tissue sarcoma	Primary	Phase III	View
Kaposi's sarcoma	Primary	Phase II	View
Glioblastoma	Primary	Phase II	View
Lung non-small cell carcinoma			View
Pancreatic ductal adenocarcinoma			View


This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use DOXIL safely and effectively. See full prescribing information for DOXIL.

DOXIL® (doxorubicin HCl liposome injection) for intravenous infusion
Initial U.S. Approval: 1995

WARNING: INFUSION REACTIONS, MYELOSUPPRESSION, CARDIOTOXICITY, LIVER IMPAIRMENT, SUBSTITUTION
See full prescribing information for complete boxed warning.

- Myocardial damage may lead to congestive heart failure and may occur as the total cumulative dose of doxorubicin HCl approaches 550 mg/m². Cardiac toxicity may also occur at lower cumulative doses with mediastinal irradiation or concurrent cardiotoxic agents (5.1).
- Acute infusion-related reactions, sometimes reversible upon terminating or slowing infusion, occurred in up to 10% of patients. Serious and sometimes fatal allergic/anaphylactoid-like infusion reactions have been reported. Medications/emergency equipment to treat such reactions should be available for immediate use (5.2).
- Severe myelosuppression may occur (5.3)
- Reduce dosage in patients with impaired hepatic function (2.6).
- Accidental substitution of DOXIL resulted in severe side effects. Do not substitute on mg per mg basis with doxorubicin HCl (2.1).

FDA文件的pdf

CAS
A division of the American Chemical Society

配體藥理學資訊







CAS
A division of the American Chemical Society

配體ADME信息



CAS
A division of the American Chemical Society

配體毒理學資訊



CAS
A division of the American Chemical Society

配體相關靶點與疾病資訊

基於CAS數據關聯，一鍵關聯到該配體相關靶點與疾病資訊詳情頁，並探索更多關聯資訊



CAS
A division of the American Chemical Society

配體相關免疫療法資訊

Summary | Pharmacology | ADME | Toxicology | Proteins (313) | Diseases (301) | **Related Immunotherapeutics (12)** | Chemical Space | Metabolites (4) | Similar Ligands (764)

MAb-DMBA-SIL-Dox



抗體與配體結構資訊

Antibody	Cetuximab
Antigen	Epidermal growth factor receptor (EGFR)
Payload	Doxorubicin
Therapeutic Target	DNA topoisomerase 2-alpha
Drug-Antibody Ratio	5.57
Linker	DMBA-SIL
Method	Site-specific conjugation with the respective EGFR mAb via thiolmaleimide Michael addition.

免疫療法詳情

Trastuzumab-PC4AP-DOX



Antibody	Trastuzumab
Antigen	Receptor tyrosine-protein kinase erbB-2 (ERBB2)
Payload	Doxorubicin
Therapeutic Target	DNA topoisomerase 2-alpha
Drug-Antibody Ratio	2
Linker	Photocaged C4AP
Method	Random conjugation through reduced inter-chain cysteines.

CAS
A division of the American Chemical Society

ADC藥物詳情

Trastuzumab emtansine

CAS Registry Number: 1018448-65-1

1,972 | 8 | Retrosynthesis | Predictive Analytics | ...

Summary | Pharmacology | ADME | Proteins (2) | Diseases (1)

Antibody	Trastuzumab
Antigen	Receptor tyrosine-protein kinase erbB-2 (ERBB2)
Payload	Mertansine DM1
Therapeutic Target	Microtubule
Drug-Antibody Ratio	3.5
Linker	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
Method	Random conjugation through nucleophilic lysines.

ADC藥物詳情



抗體3D結構圖

藥物分子結構



CAS DRUG INTELLIGENCE

藥物情報資訊

Approved Drug

Trastuzumab emtansine (ado-trastuzumab emtansine, trade name Kadcyla) is a combination between a monoclonal antibody and a small-molecule drug. Each molecule of trastuzumab emtansine consists of a single trastuzumab molecule with several molecules of DM1, a cytotoxic maytansinoid, attached. SMCC, or...

View More

STATUS	**Approval Status:** US Approved **Approval Authority:** US FDA **Approval Year:** 2013 **Originator:** Genentech
INDICATIONS	Breast cancer **Modality:** Primary **Highest Phase:** Approved Source
PRIMARY TARGET	Receptor tyrosine-protein kinase erbB-2 **Function:** Blocker Source

Heavy Chain Sequence

EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYSRWGGDG
FYAMDYDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL
TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

重鏈/輕鏈序列

Light Chain Sequence

DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYQQHYTTPPTPTFGQG
TKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPV
TKSFNRGEC

HCDR1	HCDR2	HCDR3	LCDR2	LCDR1	LCDR3
GFNIKDTY	IYPTNGYT	SRWGGDGFYAMDY	SAS	QDVNTA	QQHYTTPPT

CDR序列

CAS
A division of the American Chemical Society

相似配體結構與可視化分析



CAS
A division of the American Chemical Society

探索配體代謝產物

已知代謝產物：Known
預測代謝產物：Confidence Score置信度分值，表示發生該生物轉化的概率

CAS
A division of the American Chemical Society

大綱

- CAS BioFinder簡介與檢界面介紹（介紹與介面）
- 配體檢索與配體詳情信息（配體與細節概述）
- **骨架檢索與構效關係分析（支架與搜救分析）**
- 蛋白/通路/靶點、疾病與生物標誌物（Proteins and Pathways; 疾病與生物標記）
- 生物活性預測（Predictive Analytics ）

基於靶點或結構片段，探索活性結構骨架

繪製核心結構片段





歸一化的活性

篩選關注的靶點

$$pKa = -\log_{10} Ka$$

$$pIC50 = -\log_{10} IC50$$

IC50越小，pValue越大，抑制活性越高。

CAS
A division of the American Chemical Society

探索目標結構骨架的SAR數據



CAS
A division of the American Chemical Society

探索目標結構骨架的SAR數據



CAS
A division of the American Chemical Society

符合分子對分析（MMPA）



CAS
A division of the American Chemical Society

符合分子對分析（MMPA）

快速直觀獲取匹配分子對ΔpActivity熱圖



CAS
A division of the American Chemical Society

查看同一結構骨架中的配體藥理活性



CAS
A division of the American Chemical Society

獲取與目標骨架相似骨架結構，啟發新的SAR假設



獲取相似骨架結構(Similar Scaffolds)；

基於相應藥效團的關鍵結構元素識別相似骨架結構

CAS
A division of the American Chemical Society

大綱

- CAS BioFinder簡介與檢界面介紹（介紹與介面）
- 配體檢索與配體詳情信息（配體與細節概述）
- 骨架檢索與構效關係分析（支架與搜救分析）
- **蛋白/通路/靶點、疾病與生物標誌物（Proteins and Pathways; 疾病與生物標記）**
- 生物活性預測（Predictive Analytics ）

通過靶點、疾病或配體，獲取歸一化的蛋白檢索結果



CAS
A division of the American Chemical Society

蛋白詳情資訊與立體結構展示

SYK
Tyrosine-protein kinase SYK

Summary | Pharmacology | Ligands (31K) | Diseases (388) | Chemical Space | Pathways

Crystal structure of the syk tyrosine kinase domain with Staurosporin



蛋白的三維晶體結構及與其相互作用的小分子

STAUROSPORINE
1XBC | Model 1 | Instance ASM_1 | B [auth A] | STU 1

1XBC | 下載cif格式結構檔

Homo sapiens
unspecified
Rattus norvegicus
Mus musculus

來源有機體

Organism
Homo sapiens | GET FASTA | Copy Sequence

```
>P43405-1|Tyrosine-protein kinase SYK|Homo sapiens
MASSGMADSANHLPFFFGNITREEAEDYLVQGGMSDGLYLLRQSRNYLGGFALSVAHGRKAHHYTIERELNGTYAIAGGRTHASPADLCHYHSQESDGLVCLLKKPFNRPQGVQPK
TGPFEDLKENLIREYVKQTWNLQGQALEQAIISQKPQLEKLIATTAHEKMPWFHGKISREESEQIVLIGSKTNGKFLIRARDNNGSYALCLLHEGKVLHYRIDKDKTGKLSIPEGK
KFDTLWQLVEHYSYKADGLLRVLTVPCQKIGTQGNVNFGGRPQLPGSHPATWSAGGIISRIKSYSFPKPGHRKSSPAQGNRQESTVSFNPYEPELAPWAADKGPQREALPMDTEVY
ESPYADPEEIRPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNR
HVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSE
VTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN
```

序列詳情

Identifier	Method	Resolution	Chain	Positions	Source
1A81	X-Ray	3.0 Å	A/C/E/G/I/K	9 - 262	PDB
1CSY	NMR	-	A	163 - 265	PDB
1CSZ	NMR	-	A	163 - 265	PDB
1XBA	X-Ray	2.00 Å	A	353 - 635	PDB
1XBB	X-Ray	1.57 Å	A	353 - 635	PDB
1XBC	X-Ray	2.00 Å	A	353 - 635	PDB
3BUW	X-Ray	1.450 Å	A/C	317 - 329	PDB
				349 - 635	PDB

歸一化的靶點名稱與其他詳情資訊

Synonyms

Spleen associated tyrosine kinase
Spleen tyrosine kinase

External Links and Identifiers

Alliance of Genome Resources: HGNC:11491
CHEMBL: CHEMBL2599
Ensembl gene: ENSG00000165025.15, ENSG00000165025
HGNC: HGNC:11491
NCBI Gene: 6850
OMIM: 600085
Uniprot reviewed: P43405
View Less

CAS
A division of the American Chemical Society

相關配體與藥理活性數據



CAS
A division of the American Chemical Society

蛋白相關疾病資訊



CAS
A division of the American Chemical Society

蛋白的生物通路資訊



CAS
A division of the American Chemical Society

通過疾病名稱、靶點或配體檢索相關疾病資訊



CAS
A division of the American Chemical Society

疾病詳情頁與相關藥物資訊



CAS
A division of the American Chemical Society

疾病與生物標誌物



CAS
A division of the American Chemical Society

大綱

- CAS BioFinder簡介與檢界面介紹（介紹與介面）
- 配體檢索與配體詳情信息（配體與細節概述）
- 骨架檢索與構效關係分析（支架與搜救分析）
- 蛋白/通路/靶點、疾病與生物標誌物（Proteins and Pathways; 疾病與生物標記）
- **生物活性預測（Predictive Analytics）**

Predictive Analytics：通過演算法預測配體對不同靶點的生物活性數據







CAS
A division of the American Chemical Society

可從檢索結果集中添加配體結構



CAS
A division of the American Chemical Society

不同的蛋白靶點面板說明



Panels

+ Create New Panel

Search panels by name...

点击查看详细靶点名称列表

Panel Name	Description	Targets
CAS Full Pharmacology (Default)	The full panel of protein target models available through CAS to highlight potential safety concerns and treatment options	All
CAS Broad Safety Screen	A diverse panel of protein targets to widely test the safety of your drug candidate	192
CAS Medium Safety Screen	Panel of protein targets likely to be implicated to adverse drug reactions (ADRs) based off of known structure activity relationships (SARs)	115
CAS Narrow Safety Screen	Panel of protein targets established as being involved in adverse drug reactions (ADRs). These targets are essential for early safety screening of drugs	49
CAS Alzheimer's Disease Screen	Panel of protein targets potentially implicated in Alzheimer's Disease	81
CAS Breast Cancer Screen	Panel of protein targets potentially implicated in breast cancer and neoplasms	70
CAS Colon Cancer Screen	Panel of protein targets potentially implicated in colon cancer and neoplasms	92
CAS Depressive Disorder Screen	Panel of protein targets potentially implicated in depressive disorder and major depressive disorder	51
CAS Diabetes Screen	Panel of protein targets potentially implicated in diabetes	78
CAS Inflammation Screen	Panel of protein targets potentially implicated in inflammation	33
CAS Liver Cancer Screen	Panel of protein targets potentially implicated in liver cancer and neoplasms	73
CAS Lung Cancer Screen	Panel of protein targets potentially implicated in lung cancer and neoplasms	66
CAS Parkinson's Disease Screen	Panel of protein targets potentially implicated in Parkinson's disease	46
CAS Prostate Cancer Screen	Panel of protein targets potentially implicated in prostate cancer and neoplasms	70

CAS
A division of the American Chemical Society

自訂靶點面板



生物活性預測結果

使用左側篩選功能可對這些數據進行細化分析：
- 活性值(pActivity)
- 置信度分數(Confidence score)
- 靶點(Target)
- 有機體(Organism)

助於探索特定範圍內的pAct, 或有較高可信度的預測資訊。

CAS
A division of the American Chemical Society

總結

配體檢索 (Ligands)

- 基於藥物名稱、CAS RN、結構、靶點、疾病等，獲取配體資訊
- 通過類藥性、ADME、實驗參數、藥物功能、生物有機體等，進行篩選聚焦
- 查看並評估化合物的藥理學、ADME、毒理學和代謝物資訊及可視化展示

骨架檢索(Scaffolds)

- 基於結構或靶點等資訊，高效獲取相關骨架結構，並通過官能團R-Groups，進行構效關係分
- 通過 SAR 以及MMPA，優化目標骨架或先導化合物的效力和選擇性
- 探索針對關注靶點同一結構骨架中活性最高的配體，獲取相似骨架結構與拓展

蛋白/通路/靶點與疾病檢索(Proteins & Diseases)

- 高效獲取蛋白質通路/靶點與疾病生物標誌物資訊，探索藥物作用機制和適應症

預測配體 與不同靶點的生物活性(Predictive Analytics)

- 預測特定結構針對特定靶點的藥理活性資訊
- 關注配體的脫靶效應與藥物再利用

CAS
A division of the American Chemical Society

相關資源Learn More

https://biofinder.cas.org/

獲取CAS BioFinder登錄訪問網址

https://www.cas.org/solutions/biofinder-discovery-platform

瞭解更多關於CAS BioFinder的資訊

https://cas-biofinder.zendesk.com/hc/en-us

獲取CAS BioFinder使用說明資訊

獲取更多技術支援與說明，請聯繫：tliu2@acs-i.org

CAS
A division of the American Chemical Society

Between problems and progress are connections that matter

謝謝！

tliu2@acs-i.org

美国化学文摘社(CAS)

+886-975-765-358

CAS
A division of the American Chemical Society